Loading...

MedXY AI/MedXY News/Tag: clinical trial

MedXY News

EnglishTag

clinical trial

172 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial

Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial

The endTB-Q trial assessed the efficacy and safety of a shortened BDLC regimen versus WHO standard care in rifampicin-resistant and fluoroquinolone-resistant tuberculosis, finding BDLC non-inferior in mITT but overall not non-inferior, high

Section: Clinical UpdatesOct 9, 2025

Candesartan 16 mg Shows Promise for Episodic Migraine Prevention: Results from a Robust Phase 2 Randomised Trial

Candesartan 16 mg Shows Promise for Episodic Migraine Prevention: Results from a Robust Phase 2 Randomised Trial

A multi-center, triple-blind phase 2 trial demonstrates that daily candesartan 16 mg significantly reduces migraine days in episodic migraine patients, with tolerable safety profiles, supporting its role as an effective preventive option.

Section: Neurology

Oct 9, 2025

Dual Immune Checkpoint Blockade Fails to Improve Outcomes in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007 Phase II Study Results

Dual Immune Checkpoint Blockade Fails to Improve Outcomes in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007 Phase II Study Results

The NRG Oncology BN007 trial found that combining ipilimumab with nivolumab did not improve progression-free survival compared to temozolomide in patients with newly diagnosed MGMT-unmethylated glioblastoma, leading to early closure of the

Section: newsOct 9, 2025

Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial

Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial

The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and

Section: Clinical UpdatesOct 9, 2025

Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

The NuTide:121 phase III trial compared NUC-1031/cisplatin to gemcitabine/cisplatin in treatment-naïve advanced biliary tract cancer but was terminated early due to lack of survival benefit and increased liver toxicity with NUC-1031.

Section: Clinical UpdatesOct 9, 2025

Reevaluating Early Blood Pressure Targets in Acute Spinal Cord Injury: Insights from a Multicenter Randomized Trial

Reevaluating Early Blood Pressure Targets in Acute Spinal Cord Injury: Insights from a Multicenter Randomized Trial

A recent randomized clinical trial comparing augmented to conventional blood pressure targets in acute spinal cord injury found no improvement in 6-month neurological outcomes, challenging current practices and highlighting risks of higher

Section: Clinical UpdatesOct 9, 2025

Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial

Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial

This phase III trial showed that adding lobeglitazone to metformin and sitagliptin significantly improves glycaemic control and insulin sensitivity with favorable safety over 52 weeks in Korean patients with type 2 diabetes inadequately con

Section: Clinical UpdatesOct 8, 2025

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

Oral semaglutide 25 mg once daily significantly reduces body weight versus placebo and improves physical function in adults with overweight or obesity, offering an alternative to injectable formulations.

Section: Diabetes & EndocrinologyOct 8, 2025

Hydroxytyrosol Supplementation Enhances Antioxidant and Anti-Inflammatory Status in Overweight Prediabetic Adults: Insights from a Randomized Controlled Trial

Hydroxytyrosol Supplementation Enhances Antioxidant and Anti-Inflammatory Status in Overweight Prediabetic Adults: Insights from a Randomized Controlled Trial

A 16-week randomized trial demonstrates that daily hydroxytyrosol supplementation significantly reduces oxidative stress and inflammatory markers in overweight individuals with prediabetes, highlighting its potential in preventing aging-rel

Section: Diabetes & EndocrinologyOct 8, 2025

Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial

Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial

The ENDOLA trial explored olaparib with metronomic cyclophosphamide and metformin, demonstrating a favorable safety profile and promising efficacy in heavily pretreated recurrent endometrial cancer patients, highlighting molecular subtype-d

Section: Clinical UpdatesOct 8, 2025

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm,

Section: OB/GYN & Women's HealthOct 8, 2025

Oral Metformin in Non-Muscle-Invasive Bladder Cancer: Insights from a Phase II Marker Lesion Study

Oral Metformin in Non-Muscle-Invasive Bladder Cancer: Insights from a Phase II Marker Lesion Study

A phase II trial assessing oral metformin for low-grade non-muscle-invasive bladder cancer (NMIBC) found minimal antitumor activity and no significant mechanistic changes, challenging metformin’s role as an intravesical therapeutic agent in

Section: Clinical UpdatesOct 8, 2025

Evaluating AI-Enhanced EMG Reporting: Insights from a Randomized Controlled Trial

Evaluating AI-Enhanced EMG Reporting: Insights from a Randomized Controlled Trial

An RCT evaluated an AI-assisted framework for electrodiagnostic report interpretation, finding no significant improvement over standard physician reporting but highlighting potential workflow benefits for routine cases.

Section: AIOct 8, 2025

Preoperative versus Postoperative Stereotactic Radiation Therapy for Brain Metastases: Safety, Feasibility, and Efficiency Insights from a Phase 3 Randomized Trial

Preoperative versus Postoperative Stereotactic Radiation Therapy for Brain Metastases: Safety, Feasibility, and Efficiency Insights from a Phase 3 Randomized Trial

A phase 3 randomized trial demonstrates that preoperative stereotactic radiation therapy (SRT) for brain metastases offers comparable safety and reduced treatment duration compared to postoperative SRT, potentially improving patient care lo

Section: Clinical UpdatesOct 8, 2025

High-Dose Aumolertinib Demonstrates Promising Efficacy in Untreated EGFR-Mutant NSCLC with Brain Metastases: Insights from the ACHIEVE Phase 2 Trial

High-Dose Aumolertinib Demonstrates Promising Efficacy in Untreated EGFR-Mutant NSCLC with Brain Metastases: Insights from the ACHIEVE Phase 2 Trial

The ACHIEVE Phase 2 trial reveals that high-dose aumolertinib offers significant intracranial and systemic control with a manageable safety profile in patients with untreated EGFR-mutant NSCLC and brain metastases, highlighting its therapeu

Section: Clinical UpdatesOct 8, 2025

Transcutaneous Auricular Vagus Nerve Stimulation: A Novel Approach to Managing Postpartum Uterine Contraction Pain after Cesarean Delivery

Transcutaneous Auricular Vagus Nerve Stimulation: A Novel Approach to Managing Postpartum Uterine Contraction Pain after Cesarean Delivery

A randomized clinical trial shows that transcutaneous auricular vagus nerve stimulation significantly reduces postpartum uterine contraction pain, incisional pain, anxiety, and depression, enhancing recovery and sleep quality in cesarean de

Section: AnesthesiologyOct 8, 2025

Esketamine Monotherapy for Treatment-Resistant Depression: A New Therapeutic Frontier

Esketamine Monotherapy for Treatment-Resistant Depression: A New Therapeutic Frontier

A phase 4 randomized trial demonstrates that esketamine nasal spray monotherapy significantly reduces depressive symptoms in adults with treatment-resistant depression, offering a promising alternative to oral antidepressants.

Section: newsOct 8, 2025

Evaluating Intra-Arterial Tenecteplase Post-Thrombectomy in Large Vessel Occlusion Stroke: Safety and Early Efficacy from a Dose-Escalation Randomized Trial

Evaluating Intra-Arterial Tenecteplase Post-Thrombectomy in Large Vessel Occlusion Stroke: Safety and Early Efficacy from a Dose-Escalation Randomized Trial

Adjunctive intra-arterial tenecteplase after successful reperfusion in anterior circulation large vessel occlusion stroke demonstrates an acceptable safety profile at low doses, supporting further investigation into its therapeutic potentia

Section: NeurologyOct 8, 2025

Medication Adherence in Hypertension: Insights from the TEAMLET Cluster Randomized Clinical Trial and Related Advances

Medication Adherence in Hypertension: Insights from the TEAMLET Cluster Randomized Clinical Trial and Related Advances

TEAMLET trial reveals limited impact of EHR-pharmacy linked interventions on medication adherence in hypertension, highlighting complexity of adherence barriers and the need for multifaceted, patient-centered strategies.

Section: CardiologyOct 8, 2025

Evaluating Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from the ODYSSEY-HCM Trial

Evaluating Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from the ODYSSEY-HCM Trial

A phase 3 trial found mavacamten did not significantly improve exercise capacity or symptoms in adults with symptomatic nonobstructive hypertrophic cardiomyopathy compared to placebo, despite its efficacy in obstructive HCM.

Section: CardiologyOct 7, 2025

Prev 1 3 4 5 6 7 9 Next